Shepherd, James
National Health and Medical Research Council
21 papers on CoChat
Most cited papers
- Verified
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine
Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research
Cited by 7,449
- Verified
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine
Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases
Cited by 6,674
- Verified
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine
Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research
Cited by 3,489
- Verified
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet
Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism
Cited by 3,378
- Verified
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet
Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism
Cited by 2,436
- Verified
Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study
Sattar, N., Gaw, A., Scherbakova, O., Ford, I., O’Reilly, D. S. J., Haffner, S. M., Isles, C., Macfarlane, P. W., Packard, C. J., Cobbe, S. M., et al. (2003) · Circulation
Diabetes, Cardiovascular Risks, and LipoproteinsLipoproteins and Cardiovascular Health
Cited by 1,506
- Verified
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · The Lancet
Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism
Cited by 1,010
- Verified
Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study
Freeman, D. J., Norrie, J., Sattar, N., Neely, R. D. G., Cobbe, S. M., Ford, I., Isles, C., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., et al. (2001) · Circulation
Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 844
- Verified
Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes
Shepherd, J., Barter, P., Carmena, R., Deedwania, P., Fruchart, J.-C., Haffner, S., Hsia, J., Breazna, A., LaRosa, J., Grundy, S., et al. (2006) · Diabetes Care
Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 525
- Verified
Long-term follow-up of the West of Scotland Coronary Prevention Study
Ford, I., Murray, H., Packard, C. J., Shepherd, J., Macfarlane, P. W., & Cobbe, S. M. (2007) · New England Journal of Medicine
Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research
Cited by 416
- Verified · note
Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk Factors: The Prospective Pravastatin Pooling Project
Sacks, F. M., Tonkin, A. M., Shepherd, J., Braunwald, E., Cobbe, S., Hawkins, C. M., Keech, A., Packard, C., Simes, J., Byington, R., et al. (2000) · Circulation
Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism
Cited by 388
- Verified
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study
Deedwania, P., Barter, P., Carmena, R., Fruchart, J.-C., Grundy, S. M., Haffner, S., Kastelein, J. J., LaRosa, J. C., Schachner, H., Shepherd, J., et al. (2006) · The Lancet
Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 387
- Verified
Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney Disease
Shepherd, J., Kastelein, J. J. P., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A., & Wenger, N. K. (2008) · Journal of the American College of Cardiology
Lipoproteins and Cardiovascular HealthChronic Kidney Disease and Diabetes
Cited by 302
- Verified
From patients to partners: participant-centric initiatives in biomedical research
Kaye, J., Curren, L., Anderson, N., Edwards, K., Fullerton, S. M., Kanellopoulou, N., Lund, D., MacArthur, D. G., Mascalzoni, D., Shepherd, J., et al. (2012) · Nature Reviews Genetics
Ethics in Clinical ResearchSocial Media in Health Education
Cited by 293
- Verified
Effect of Intensive Lipid Lowering with Atorvastatin on Renal Function in Patients with Coronary Heart Disease: The Treating to New Targets (TNT) Study
Shepherd, J., Kastelein, J. J. P., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A., & Wenger, N. K. (2007) · Clinical Journal of the American Society of Nephrology
Lipoproteins and Cardiovascular HealthChronic Kidney Disease and Diabetes
Cited by 275
- Verified
Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial
Glynn, R. J., Koenig, W., Nordestgaard, B. G., Shepherd, J., & Ridker, P. M. (2010) · Annals of Internal Medicine
Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism
Cited by 252
- Verified
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis
Reith, C., Preiss, D., Blackwell, L., Emberson, J., Spata, E., Davies, K., Halls, H., Harper, C., Holland, L., Wilson, K., et al. (2024) · The Lancet Diabetes & Endocrinology
Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 161
- Verified
Unraveling the directional link between adiposity and inflammation: A bidirectional Mendelian randomization approach
Welsh, P., Polisecki, E., Robertson, M., Jahn, S., Buckley, B. M., de Craen, A. J. M., Ford, I., Jukema, J. W., Macfarlane, P. W., Packard, C. J., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism
Adipokines, Inflammation, and Metabolic DiseasesGenetic Associations and Epidemiology
Cited by 140
- Verified · note
Serial Metabolic Measurements and Conversion to Type 2 Diabetes in the West of Scotland Coronary Prevention Study
Sattar, N., McConnachie, A., Ford, I., Gaw, A., Cleland, S. J., Forouhi, N. G., McFarlane, P., Shepherd, J., Cobbe, S., & Packard, C. (2007) · Diabetes
Diabetes, Cardiovascular Risks, and LipoproteinsLiver Disease Diagnosis and Treatment
Cited by 127
- Verified
Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)
Packard, C. J., Ford, I., Robertson, M., Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L. E. M., Buckley, B. M., Cobbe, S. M., Gaw, A., et al. (2005) · Circulation
Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism
Cited by 121
- Verified
Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates
Forster, L. F., Stewart, G., Bedford, D., Stewart, J. P., Rogers, E., Shepherd, J., Packard, C. J., & Caslake, M. J. (2002) · Atherosclerosis
Lipoproteins and Cardiovascular HealthLipid metabolism and disorders
Cited by 77
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free